trending Market Intelligence /marketintelligence/en/news-insights/trending/W2feitc3Pdbf-LjN_TkB4A2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

CTI BioPharma plans public offering of preferred stock

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


CTI BioPharma plans public offering of preferred stock

CTI BioPharma plans to sell series N-3 convertible preferred stock at $1,000 apiece in an underwritten public offering.

The company said it plans to use net proceeds for the development and marketing approval of its bone marrow drug pacritinib, as well other clinical trials and general corporate purposes.

Jefferies LLC will act as the sole book-running manager for the offering, which will be priced at a later date.